The Role of Platelet TLRs in Platelet Activation During VTE

Launched by CENTRE HOSPITALIER UNIVERSITAIRE DE SAINT ETIENNE · Feb 6, 2024

Keywords

ClinConnect Summary

This clinical trial is exploring the role of platelets, which are small cells in your blood, in the development of complications that can occur after a condition called venous thromboembolism (VTE). VTE includes problems like deep vein thrombosis (DVT) and pulmonary embolism, which can lead to serious health issues. The researchers want to understand how platelets contribute to inflammation and how this may lead to ongoing issues after a VTE event, like post-thrombotic syndrome or post-pulmonary embolism syndrome.

To participate in this trial, you need to be at least 18 years old and have been diagnosed with VTE or DVT within the last 72 hours. You should also be able to provide written consent and have social security coverage. If you have certain conditions or are taking specific medications, like blood thinners or anti-inflammatory drugs, you may not be eligible. If you join the trial, you'll be contributing to important research that could help improve treatment and understanding of VTE and its long-term effects.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients diagnosed with Venous ThromboEmbolic (VTE) / Proximal Deep vein thrombosis (DVT) of the lower limb and/or pulmonary embolism ≤ 72heures
• • Patients are 18 years of age or older at diagnosis.
• • Patients received informed written consent
• • Patients benefiting from social security coverage
• Exclusion Criteria:
• • Diagnosis of Venous ThromboEmbolic (VTE) more than 72 hours old
• • Isolated sub-segmental pulmonary embolism
• • Patients on antiplatelet agents
• • Patients on non-steroidal anti-inflammatory drugs (NSAIDs)
• • Life expectancy \> 3 months